本文選題：藥品專利 + 仿制藥��； 參考：《華中科技大學》2013年碩士論文

【摘要】：TRIPS協(xié)議將藥品納入了專利保護范圍之后，仿制藥工業(yè)的知識產(chǎn)權風險變得突出，同時專利藥的價格上漲，，引起了發(fā)展中國家的用藥緊張和公共健康危機。盡管之后的《TRIPS協(xié)議與公共健康多哈宣言》及《關于TRIPS協(xié)議和公共健康多哈宣言第六段的執(zhí)行決議》提出了發(fā)展中成員要求防止濫用知識產(chǎn)權阻礙社會經(jīng)濟發(fā)展的愿望，但仍有許多具體適用上的限制性規(guī)定或障礙。在醫(yī)療開支居高不下的壓力和大批醫(yī)藥專利即將到期的利好形勢下，仿制藥已受到包括發(fā)達國家和發(fā)展中國家的重視，近年來發(fā)展迅速。出于對本國大型制藥公司的利益保護，發(fā)達國家對外仍推行高水平的知識產(chǎn)權保護水平，對于一些發(fā)展中國家利用TRIPS協(xié)議靈活性條款作出的醫(yī)藥專利強制許可等采取打壓政策。本文就藥品專利與公共健康之間的沖突原因和協(xié)調(diào)途徑進行了分析和論證，并對我國相關的藥品專利制度提出建議。 作為人口大國，保障藥品的可及性是我國面臨的現(xiàn)實挑戰(zhàn)。我國目前97%以上的國產(chǎn)藥為仿制藥。但是很多企業(yè)仍處于低水平重復仿制的狀態(tài)，帶有盲目性和風險性，不能充分掌握知識產(chǎn)權規(guī)則。通過對藥品仿制過程中的專利風險進行分析與控制，我國相關制藥企業(yè)能夠有效防范專利侵權風險，取得經(jīng)濟效益和社會效益的最大化，為我國的公共健康事業(yè)作出貢獻。
[Abstract]:After trips brought the drug into the scope of patent protection, the intellectual property risk of generic medicine industry became prominent, and the price of patent medicine increased, which caused the tension of drug use and public health crisis in developing countries. Although the subsequent Doha Declaration on trips and Public Health and the implementation resolution on trips and paragraph 6 of the Doha Declaration on Public Health set out the aspirations of developing members to prevent the abuse of intellectual property rights from impeding socio-economic development, However, there are still many restrictive provisions or obstacles to their specific application. Under the pressure of high medical expenditure and the favorable situation that a large number of medical patents are about to expire, generic drugs have been attached great importance to by both developed and developing countries, and have developed rapidly in recent years. In order to protect the interests of domestic large pharmaceutical companies, developed countries still implement a high level of intellectual property rights protection, and some developing countries take measures to suppress the compulsory licensing of pharmaceutical patents, which are made by some developing countries using the flexible terms of trips Agreement. This paper analyzes and proves the conflict between drug patent and public health and the ways of coordination, and puts forward some suggestions on the relevant drug patent system in China. As a large country with large population, it is a realistic challenge for our country to guarantee the accessibility of drugs. At present, more than 97% of domestic drugs in China are generic drugs. However, many enterprises are still in the state of low level repeated copying, with blindness and risk, unable to fully grasp the intellectual property rules. By analyzing and controlling the patent risk in the process of drug imitation, the related pharmaceutical enterprises in our country can effectively guard against the risk of patent infringement, maximize the economic and social benefits, and contribute to the public health in our country.
【學位授予單位】：華中科技大學
【學位級別】：碩士
【學位授予年份】：2013
【分類號】：D923.42

【參考文獻】

相關期刊論文 前10條

1 丁錦希;郭璇;;仿制藥注冊的專利問題研究——基于美國LILLY與TEVA制藥公司藥品專利侵權糾紛案的實證分析[J];中國發(fā)明與專利;2011年10期

2 李先波;李良才;;藥品專利權與生命健康權的沖突與協(xié)調(diào)[J];法學雜志;2009年01期

3 鄭亮;;淺議藥品專利保護與公共健康危機的平衡——以TRIPS協(xié)議下發(fā)展中國家藥品的可及性為視角[J];法制與社會;2008年21期

4 劉斌斌;王心罡;;醫(yī)藥品專利的特點及其保護困境[J];甘肅科技;2011年09期

5 徐海筠;;TRIPS協(xié)議下公共健康問題的發(fā)展及我國的應對[J];廣西政法管理干部學院學報;2006年03期

6 張俊祥;李振興;;藥物開發(fā)策略:關注仿制藥及其高端產(chǎn)品[J];創(chuàng)新科技;2010年07期

7 武艷嬌;薛佳慧;李玉秋;;仿制藥的專利風險分析與控制[J];中國發(fā)明與專利;2011年12期

8 路艷娥;;健康權的法理學思考[J];河北法學;2009年03期

9 許關煜;;仿制藥品開發(fā)中的專利問題[J];精細與專用化學品;2007年09期

10 孫捷;;企業(yè)專利預警評價體系分析方法的探討[J];科技與法律;2011年05期

本文編號：2059888